The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

The global Parkinson’s disease (PD) market is expected to grow to $7.9 billion by 2033 from $3.4 billion in 2023, according ...

USE ONAPGO is a prescription medicine used to treat motor fluctuations (OFF episodes) in adults with advanced Parkinson’s disease (PD). It is not known if ONAPGO is safe and effective in children.

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...

The symptoms of Parkinson’s disease could be reversed through injections of nanoparticles into the brain, which is a much ...

The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...

Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.